FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2758628500> ?p ?o ?g. }

• W2758628500 abstract "9512 Background: Most patients treated with BRAF inhibitors (BRAFi) +/- MEK inhibitors (MEKi) eventually progress on treatment. Along with genetic acquired resistance, epigenetic mechanisms that could be reversed after BRAFi discontinuation have been described. The purpose of this study was to analyse outcomes for patients (pts) retreated with BRAF-directed therapy. Methods: 116 pts who received BRAFi based therapy and, after a break, were re-challenged with BRAFi +/- MEKi treated at 14 centres in Europe, US, and Australia were analysed for progression free survival (PFS) and response rate (RR), as well as factors predicting overall survival (OS) (demographics, disease stage, treatment, LDH level, duration of first BRAFi treatment, reason for first BRAFi discontinuation and interval between BRAFi stop and re-challenge). Multivariate Cox regression, regression trees and Kaplan Meier method were used. Results: Median duration of 1 st BRAFi +/- MEKi treatment was 9.4 months (mts) and 7.7 mts for the subsequent treatment after discontinuation (immunotherapy 72%, other 17 %, drug holiday 11%). Brain metastases were present in 51 pts (44%). RR to re-challenge with BRAFi +/- MEKi was 43%: complete response (CR) 3%, partial response (PR) 39%, stable disease 24% and progressive disease (PD) 30%, 4% missing. Of 80 pts who previously discontinued BRAFi for PD, 31 (39%) responded (30 PR and 1 CR). Median OS from retreatment was 9.8 mts. Independent prognostic factors for survival at re-challenge included number of metastatic sites (HR = 1.32 for each additional organ with metastases, p < .001), LDH (HR = 1.37 for each multiple of the upper normal limit, p < .001), while combination of BRAFi+MEKi conferred a better prognosis vs BRAFi alone (HR = 0.5, p = .006). Pts with < 3 metastatic sites treated with BRAFi and MEKi had a better survival (median OS not reached) and pts with ≥ 3 metastatic sites and raised LDH treated with BRAFi alone had the worse outcome (median OS 4 mts). Number of metastatic sites (HR = 1.44, p < .001) and combination of BRAFi and MEKi (HR = 0.45, p < .001) were independent prognostic factors for PFS (median 5.0 mts). Conclusions: Re-challenge with BRAFi +/- MEKi induces a clinically significant response and should be considered for selected cases." @default.
• W2758628500 created "2017-10-06" @default.
• W2758628500 creator A5001568438 @default.
• W2758628500 creator A5008000580 @default.
• W2758628500 creator A5018536695 @default.
• W2758628500 creator A5022293880 @default.
• W2758628500 creator A5023174631 @default.
• W2758628500 creator A5029398339 @default.
• W2758628500 creator A5030289522 @default.
• W2758628500 creator A5034365278 @default.
• W2758628500 creator A5044736874 @default.
• W2758628500 creator A5048111860 @default.
• W2758628500 creator A5049229784 @default.
• W2758628500 creator A5056551842 @default.
• W2758628500 creator A5064875028 @default.
• W2758628500 creator A5069095893 @default.
• W2758628500 creator A5070576000 @default.
• W2758628500 creator A5076054848 @default.
• W2758628500 creator A5082278497 @default.
• W2758628500 creator A5082673411 @default.
• W2758628500 creator A5083061830 @default.
• W2758628500 creator A5083431383 @default.
• W2758628500 date "2017-05-20" @default.
• W2758628500 modified "2023-10-02" @default.
• W2758628500 title "Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study." @default.
• W2758628500 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.9512" @default.
• W2758628500 hasPublicationYear "2017" @default.
• W2758628500 type Work @default.
• W2758628500 sameAs 2758628500 @default.
• W2758628500 citedByCount "6" @default.
• W2758628500 countsByYear W27586285002017 @default.
• W2758628500 countsByYear W27586285002018 @default.
• W2758628500 crossrefType "journal-article" @default.
• W2758628500 hasAuthorship W2758628500A5001568438 @default.
• W2758628500 hasAuthorship W2758628500A5008000580 @default.
• W2758628500 hasAuthorship W2758628500A5018536695 @default.
• W2758628500 hasAuthorship W2758628500A5022293880 @default.
• W2758628500 hasAuthorship W2758628500A5023174631 @default.
• W2758628500 hasAuthorship W2758628500A5029398339 @default.
• W2758628500 hasAuthorship W2758628500A5030289522 @default.
• W2758628500 hasAuthorship W2758628500A5034365278 @default.
• W2758628500 hasAuthorship W2758628500A5044736874 @default.
• W2758628500 hasAuthorship W2758628500A5048111860 @default.
• W2758628500 hasAuthorship W2758628500A5049229784 @default.
• W2758628500 hasAuthorship W2758628500A5056551842 @default.
• W2758628500 hasAuthorship W2758628500A5064875028 @default.
• W2758628500 hasAuthorship W2758628500A5069095893 @default.
• W2758628500 hasAuthorship W2758628500A5070576000 @default.
• W2758628500 hasAuthorship W2758628500A5076054848 @default.
• W2758628500 hasAuthorship W2758628500A5082278497 @default.
• W2758628500 hasAuthorship W2758628500A5082673411 @default.
• W2758628500 hasAuthorship W2758628500A5083061830 @default.
• W2758628500 hasAuthorship W2758628500A5083431383 @default.
• W2758628500 hasConcept C126322002 @default.
• W2758628500 hasConcept C143998085 @default.
• W2758628500 hasConcept C167135981 @default.
• W2758628500 hasConcept C71924100 @default.
• W2758628500 hasConceptScore W2758628500C126322002 @default.
• W2758628500 hasConceptScore W2758628500C143998085 @default.
• W2758628500 hasConceptScore W2758628500C167135981 @default.
• W2758628500 hasConceptScore W2758628500C71924100 @default.
• W2758628500 hasLocation W27586285001 @default.
• W2758628500 hasOpenAccess W2758628500 @default.
• W2758628500 hasPrimaryLocation W27586285001 @default.
• W2758628500 hasRelatedWork W129690050 @default.
• W2758628500 hasRelatedWork W1980056771 @default.
• W2758628500 hasRelatedWork W2007012961 @default.
• W2758628500 hasRelatedWork W2025130458 @default.
• W2758628500 hasRelatedWork W2106728581 @default.
• W2758628500 hasRelatedWork W2113152338 @default.
• W2758628500 hasRelatedWork W2154748904 @default.
• W2758628500 hasRelatedWork W2416497094 @default.
• W2758628500 hasRelatedWork W2542245957 @default.
• W2758628500 hasRelatedWork W2592587564 @default.
• W2758628500 hasRelatedWork W2935845776 @default.
• W2758628500 hasRelatedWork W2996886932 @default.
• W2758628500 hasRelatedWork W2998778767 @default.
• W2758628500 hasRelatedWork W3005662902 @default.
• W2758628500 hasRelatedWork W3006719485 @default.
• W2758628500 hasRelatedWork W3018162086 @default.
• W2758628500 hasRelatedWork W3023401146 @default.
• W2758628500 hasRelatedWork W3139324343 @default.
• W2758628500 hasRelatedWork W658517828 @default.
• W2758628500 hasRelatedWork W2210780192 @default.
• W2758628500 isParatext "false" @default.
• W2758628500 isRetracted "false" @default.
• W2758628500 magId "2758628500" @default.
• W2758628500 workType "article" @default.